OncoMatch/Clinical Trials/NCT04136535
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Is NCT04136535 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pemetrexed and Carboplatin for nsclc stage iv.
Treatment: Pemetrexed · Carboplatin · Anlotinib — Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced Osimertinib-resistant non-squamous non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR activating mutation
Disease stage
Required: Stage III, IV
locally advanced and / or metastatic non-squamous non-small cell lung cancer (NSCLC)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib)
previously disease progression to Osimertinib (previously treated with 1st / 2nd generation EGFR-TKI or not)
Cannot have received: systemic anti-tumor therapy
Planned for systemic anti-tumor therapy during the study period or within 4 weeks prior to enrollment, including cytotoxic therapy, signal transduction inhibitors, immunotherapy (or use mitomycin C within 6 weeks prior to receiving investigational drug).
Cannot have received: radiation therapy
Radiation-rehabilitation radiotherapy (EF-RT) was performed within 4 weeks before enrollment or limited-field radiotherapy was performed for planned tumor lesions within 2 weeks before enrollment.
Lab requirements
Blood counts
hemoglobin (HB) ≥90g/L; neutrophil absolute (ANC) ≥1.5×10^9/L; platelet (PLT) ≥80×10^9/L
Kidney function
serum creatinine (Cr) ≤1.25x ULN or creatinine clearance (CCr)≥45mL/min
Liver function
total bilirubin (TBIL) ≤1.5x ULN; ALT and AST ≤2.5x ULN, if liver metastasis occurred, ALT and AST ≤5x ULN
Cardiac function
LVEF <50% excluded; myocardial ischemia or infarction above grade II, poorly controlled arrhythmias (including men with QTc ≥ 450 ms, women ≥ 470 ms); NYHA III-IV excluded
Blood routine examination criteria... Biochemical tests meet the following criteria... cardiac color Doppler ultrasound examination indicates left ventricular ejection fraction (LVEF) <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify